Clinical Characteristics and Novel ZEB2 Gene Mutation Analysis of Three Chinese Patients with Mowat-Wilson Syndrome
Xiao Han,Qianjuan Zhang,Chengcheng Wang,Bingjuan Han
DOI: https://doi.org/10.2147/PGPM.S414161
2023-08-23
Pharmacogenomics and Personalized Medicine
Abstract:Xiao Han, 1 Qianjuan Zhang, 2 Chengcheng Wang, 3 Bingjuan Han 4 1 Department of Pediatrics, Jining First People's Hospital, Jining, Shandong, 272011, People's Republic of China; 2 Department of Children's Medical Rehabilitation Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250001, People's Republic of China; 3 Department of Pediatric Surgery, Jining First People's Hospital, Jining, Shandong, 272011, People's Republic of China; 4 Department of Children's Health Prevention, The Second Children & Women's Healthcare of Jinan City, Jinan, Shandong, 271100, People's Republic of China Correspondence: Bingjuan Han, Email Purpose: Mowat-Wilson syndrome (MWS) is an autosomal dominant disease caused by a pathogenic variant of the ZEB2 gene. The main clinical manifestations include special facial features, Hirschsprung disease (HSCR), global developmental delay and other congenital malformations. Here, we summarize the clinical characteristics and genetic mutation analysis of three Chinese patients with MWS. Patients and Methods: The clinical characteristics of the patients were monitored and the treatment effect was followed up. DNA was extracted from peripheral blood and analyzed by sequencing. Whole exome sequencing was then performed. Results: Three novel ZEB2 gene mutations were identified in 3 patients (c.1147_1150dupGAAC, p.Q384Rfs&ast7, c.1137_1146del TAGTATGTCT, p.S380Nfs &ast13 and c.2718delT, p.A907Lfs&ast23). They all had special facial features, intellectual disability, developmental delay, microcephaly, structural brain abnormalities and other symptoms. After long-term regular rehabilitation treatment, the development quotient of each functional area of the patient was slightly improved. Conclusion: Our study expanded the mutation spectrum of ZEB2 and enriched our understanding of the clinical features of MWS. It also shows that long-term standardized treatment is of great significance for the prognosis of patients. Keywords: Mowat-Wilson syndrome, ZEB2, gene mutation, rehabilitation treatment, long-term follow-up Mowat-Wilson syndrome (MWS) is an autosomal dominant disease caused by a pathogenic variant of the ZEB2 gene. The main clinical manifestations include special facial features, Hirschsprung disease (HSCR), moderate to severe intellectual disability, global developmental delay, epilepsy and other congenital malformations. Special face is mainly manifested in forehead protrusion, eye distance is increased, eyebrows are widened and have horn like protrusion inside, nose tip protrusion is round, open mouth with M-shaped upper lip, small jaw, etc. In addition, other congenital malformations may include congenital heart disease, agenesis of the corpus callosum, genitourinary abnormalities (especially in men with hypospadias), and ocular defects. 1–3 The syndrome is caused by de novo mutations in one allele of zinc-finger E-box-binding homeobox 2 gene ( ZEB2 ). ZEB2 also known as ZFHX1B (zinc finger homeobox 1B) or SIP1 (Smad Interacting protein 1). 4,5 The ZEB2 protein contains a number of functional domains, including a nucleosome remodeling and deacetylase‐interaction motif, one zinc‐finger (ZF) cluster in the amino terminal region (N‐ZF), a SMAD binding domain, a homeodomain, a C‐terminal binding protein interacting domain, and one ZF cluster in the carboxyl terminal region (C‐ZF). ZEB2 is a member of the two-handed zinc-finger/homeodomain transcription factor family, it consists of nine coding exons (exons 2–10) and one non-coding exon (exon 1). 6,7 ZEB2 , like its family members, interacts with Smad1 protein and functions as a transcriptional repressor of TGF-β signaling pathway. 8 ZEB2 plays important roles in development, such as neural crest formation, gastrula formation, cardiac morphogenesis, musculoskeletal system formation, and craniofacial structure establishment. 6,7 MWS was first described in 1998 by Mowat et al, and the genetic locus was identified on chromosome 2q22-q23. 9 It has been reported that the incidence of the disease is about 1:50, 000 to 1:70, 000. 10 By reviewing the literature, it can be found that about 300 MWS patients have been reported, and about 280 ZEB2 variants have been found (Human Gene Mutation Database). 11–14 It has mainly been reported from countries such as Europe, Australia and the United States, with Japan also reporting a large number of cases. 14 35 cases of MWS and 25 pathogenic ZEB2 variants have been repo -Abstract Truncated-
pharmacology & pharmacy